A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel

A Phase 1/2, open-label study of a modified interleukin-2 fusion protein (IOV 3001) in participants with previously treated, unresectable or metastatic melanoma who will receive lifileucel.

Trial Details

NCT ID
NCT06940739
Phase
PHASE1 / PHASE2
Sponsor
Iovance Biotherapeutics, Inc.
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • IOV-3001
Locations (sample)
  • Denver, Colorado, United States|39.73915,-104.9847
  • Chapel Hill, North Carolina, United States|35.9132,-79.05584
  • Nashville, Tennessee, United States|36.16589,-86.78444
  • Greenslopes, Queensland, Australia|-27.50815,153.04951
  • Nedlands, Western Australia, Australia|-31.98184,115.8073

Key Eligibility Criteria

  • Participant must be ≥ 18 years of age at the time of signing the informed consent.
  • Participant has unresectable or metastatic melanoma.
  • Participant has melanoma not of uveal/ocular origin and experienced documented radiographic disease progression during systemic therapy with a PD-1…
  • OR Phase 1, Part 1 only: For participants with uveal melanoma, tebentafusp must have been received if available as standard of care (human leukocyt…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →